Pharmaceutical News

RSS

Men on effective HIV therapy less likely to get HBV infection, shows research

Previous studies of individuals with HIV have suggested that HIV drug regimens that included drugs active against hepatitis B virus (HBV) can decrease the risk of infection with the liver-damaging HBV.

13 Oct 2015

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

The Pharmacy Compounding Accreditation Board (PCAB) today reaffirmed the accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA.

13 Oct 2015

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease.

12 Oct 2015

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Rebiotix Inc. today announced that U.S. Food and Drug Administration has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually.

12 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it.

12 Oct 2015

High dose flu vaccines significantly reduce hospitalization risk during influenza season

In the largest nursing home study to date on the effect of high dose flu vaccine, researchers found that shots with four times the strength of standard flu shots significantly reduced the risk of being hospitalized during the influenza season. There was a 1.2 percent difference (19.7 percent versus 20.9 percent) in admission for the group that received the high dose vaccine compared to the one that received the standard dose vaccine.

12 Oct 2015

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

11 Oct 2015

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed.

11 Oct 2015

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Eli Lilly and Company and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.

11 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition products, Contract Manufacturing, and iForce Nutrition ("iForce"), one of the fastest-growing Sports Nutrition companies in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire iForce.

9 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in approximately 20 patients worldwide.

9 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults.

9 Oct 2015

Repatha (evolocumab) injection gets FDA approval for high cholesterol

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

9 Oct 2015

Pharmaceutical News

Men on effective HIV therapy less likely to get HBV infection, shows research

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

Rebiotix's RBX2660 receives FDA Breakthrough Therapy designation for treatment of recurrent C diff infection

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Lithium can be safe, effective for children suffering from bipolar disorder

High dose flu vaccines significantly reduce hospitalization risk during influenza season

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

Research finding offers hope for more powerful aspirin-like drugs

Lilly acquires worldwide rights to intranasal glucagon from Locemia

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

Hi-Tech Pharmaceuticals signs definitive agreement to acquire iForce

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

Xuriden (uridine triacetate) now approved for patients with hereditary orotic aciduria

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Vraylar (cariprazine) capsules now approved by FDA to treat schizophrenia, bipolar disorder in adults

Repatha (evolocumab) injection gets FDA approval for high cholesterol

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News